Please check your internet connection and try again.
## Overview
Mylotat is a brand name for **Mitozantrone hydrochloride**. It is an anthracenedione antineoplastic agent.
## Primary Indications
* Metastatic breast cancer
* Prostate cancer (hormone-refractory)
* Acute myeloid leukemia (AML) in adults
## Adult Dosing
* **Metastatic Breast Cancer:** 10-12 mg/m² intravenously every 3 weeks.
* **Prostate Cancer:** 10-12 mg/m² intravenously every 3 weeks.
* **Acute Myeloid Leukemia (AML):** 10-12 mg/m²/day for 3 days in combination with cytarabine.
## Pediatric Dosing
Mitozantrone is not typically recommended for pediatric use due to limited safety and efficacy data.
## Dose Adjustments
* **Hematologic Toxicity:** Dose reductions may be necessary based on nadir neutrophil count and platelet count. Consult specific protocols.
* **Hepatic Impairment:** Use with caution. Data is limited; dose reduction may be considered based on liver function.
* **Renal Impairment:** No specific dose adjustment guidelines. Use with caution.
## Contraindications
* Hypersensitivity to mitozantrone
* Severe myelosuppression
* Concomitant severe infection
## Adverse Effects
* **Hematologic:** Myelosuppression (neutropenia, thrombocytopenia, anemia) is dose-limiting and common.
* **Cardiotoxicity:** Cumulative dose-related cardiotoxicity, including congestive heart failure and decreased ejection fraction. Risk increases with prior anthracycline therapy or mediastinal radiation.
* **Gastrointestinal:** Nausea, vomiting, mucositis, diarrhea.
* **Other:** Alopecia (often reversible), secondary malignancies, extravasation injury, fatigue, liver enzyme elevations, hyperuricemia.
## Key Drug Interactions
* **Cardiotoxic Agents (e.g., anthracyclines, trastuzumab):** Increased risk of cardiotoxicity.
* **Myelosuppressive Agents:** Additive myelosuppression.
* **Live Vaccines:** Avoid concomitant use due to risk of severe infection.
## Monitoring
* Complete blood count (CBC) with differential and platelet count prior to each dose and as clinically indicated.
* Left ventricular ejection fraction (LVEF) or other assessment of cardiac function, especially with cumulative doses > 120-160 mg/m².
* Liver function tests.
* Renal function tests.
* Signs and symptoms of infection.
* Uric acid levels.
## Clinical Pearls
* Mitozantrone can cause blue-green discoloration of urine, skin, and sclera.
* Extravasation can lead to severe tissue damage; administer in a well-established IV line and monitor infusion site closely. If extravasation occurs, discontinue infusion and follow local protocol for management.
* Cardiac toxicity is a significant concern; cumulative dose should be carefully tracked.
* Nausea and vomiting are common and can be managed with antiemetics.
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date information before making any treatment decisions.
